In fairness, Larry Husten of CardioBrief flagged it, as part of a much longer article of his -- but I amplified it -- and ran it as my Arbiter 6 story lede, on Sunday night.
Now Forbes is fully on to it, thus:
. . . .Many researchers worry the study [IMPROVE-IT] could take years longer than this. In an editorial published in the New England Journal of Medicine Monday, John Kastelein of Utrecht Medical Center in the Netherlands wrote that it was "uncertain whether the trial will ever reach completion". . . .
Some say even 18,000 patients may not be enough to settle the question. Rory Collins, an Oxford University researcher who believes Zetia does prevent heart attacks, says there is a chance the study will give a false answer that there is not a difference. Heart attack rates in the study may be so low that it will be difficult to prove any difference between drug regimens. . . .